Hollings Home  
 
Chrystal M Paulos, PhD
Assistant Professor of Microbiology & Immunology
College of Medicine
MUSC

Email: paulos@musc.edu
 
       Print This Page
       
 
 


 

Chrystal M Paulos, PhD

Return to Search Page  

Research Interest:

Dr. Paulos' research focuses on the potential role of human IL-17 producing cells in tumor immunity. Currently, Dr. Paulos' laboratory is investigating how ICOS signaling modulates key transcription factors that impact the function fate of inflammatory Th17/Tc17 cells and the mechanisms governing the effectiveness of ICOS-expanded Th17/Tc17 cells using a highly clinically relevant cancer mouse model.

Selected Publications:

1.Nelson MH, Bowers JS, Bailey SR, Diven MA, Fugle CW, Kaiser AD, Wrzesinski C, Liu B, Restifo NP, Paulos CM. Toll-like receptor agonist therapy can profoundly augment the antitumor activity of adoptively transferred CD8(+) T cells without host preconditioning. J Immunother Cancer. .4:6, 2016. PMID: 26885368 PMCID: PMC4754841
View in: PubMed

2.Majchrzak K, Nelson MH, Bailey SR, Bowers JS, Yu XZ, Rubinstein MP, Himes RA, Paulos CM. Exploiting IL-17-producing CD4(+) and CD8(+) T cells to improve cancer immunotherapy in the clinic. Cancer Immunol Immunother. .65(3):247-59, 2016. PMID: 26825102
View in: PubMed

3.Su EW, Moore CJ, Suriano S, Johnson CB, Songalia N, Patterson A, Neitzke DJ, Andrijauskaite K, Garrett-Mayer E, Mehrotra S, Paulos CM, Doedens AL, Goldrath AW, Li Z, Cole DJ, Rubinstein MP. IL-2Ra mediates temporal regulation of IL-2 signaling and enhances immunotherapy. Sci Transl Med. .7(311):311ra170, 2015. PMID: 26511507
View in: PubMed

4.Andrijauskaite K, Suriano S, Cloud CA, Li M, Kesarwani P, Stefanik LS, Moxley KM, Salem ML, Garrett-Mayer E, Paulos CM, Mehrotra S, Kochenderfer JN, Cole DJ, Rubinstein MP. IL-12 conditioning improves retrovirally mediated transduction efficiency of CD8+ T cells. Cancer Gene Ther. .22(7):360-7, 2015. PMID: 26182912
View in: PubMed

5.Nelson MH, Diven MA, Huff LW, Paulos CM. Harnessing the Microbiome to Enhance Cancer Immunotherapy. J Immunol Res. .2015:368736, 2015. PMID: 26101781 PMCID: PMC4458560
View in: PubMed

6.Bowers JS, Nelson MH, Kundimi S, Bailey SR, Huff LW, Schwartz KM, Cole DJ, Rubinstein MP, Paulos CM. Dendritic Cells in Irradiated Mice Trigger the Functional Plasticity and Antitumor Activity of Adoptively Transferred Tc17 Cells via IL12 Signaling. Clin Cancer Res. .21(11):2546-57, 2015. PMID: 25904754 PMCID: PMC4452402
View in: PubMed

7.Rubinstein MP, Su EW, Suriano S, Cloud CA, Andrijauskaite K, Kesarwani P, Schwartz KM, Williams KM, Johnson CB, Li M, Scurti GM, Salem ML, Paulos CM, Garrett-Mayer E, Mehrotra S, Cole DJ. Interleukin-12 enhances the function and anti-tumor activity in murine and human CD8(+) T cells. Cancer Immunol Immunother. .64(5):539-49, 2015. PMID: 25676709
View in: PubMed

8.Frigault MJ, Lee J, Basil MC, Carpenito C, Motohashi S, Scholler J, Kawalekar OU, Guedan S, McGettigan SE, Posey AD, Ang S, Cooper LJ, Platt JM, Johnson FB, Paulos CM, Zhao Y, Kalos M, Milone MC, June CH. Identification of chimeric antigen receptors that mediate constitutive or inducible proliferation of T cells. Cancer Immunol Res. .3(4):356-67, 2015. PMID: 25600436 PMCID: PMC4390458
View in: PubMed

9.Nelson MH, Kundimi S, Bowers JS, Rogers CE, Huff LW, Schwartz KM, Thyagarajan K, Little EC, Mehrotra S, Cole DJ, Rubinstein MP, Paulos CM. The inducible costimulator augments Tc17 cell responses to self and tumor tissue. J Immunol. .194(4):1737-47, 2015. PMID: 25576595 PMCID: PMC4323681
View in: PubMed

10.Nelson MH, Paulos CM. Novel immunotherapies for hematologic malignancies. Immunol Rev. .263(1):90-105, 2015. PMID: 25510273 PMCID: PMC4277117
View in: PubMed

11.Varghese B, Vlashi E, Xia W, Ayala Lopez W, Paulos CM, Reddy J, Xu LC, Low PS. Folate receptor-ß in activated macrophages: ligand binding and receptor recycling kinetics. Mol Pharm. .11(10):3609-16, 2014. PMID: 25166491
View in: PubMed

12.Chatterjee S, Thyagarajan K, Kesarwani P, Song JH, Soloshchenko M, Fu J, Bailey SR, Vasu C, Kraft AS, Paulos CM, Yu XZ, Mehrotra S. Reducing CD73 expression by IL1ß-Programmed Th17 cells improves immunotherapeutic control of tumors. Cancer Res. .74(21):6048-59, 2014. PMID: 25205101 PMCID: PMC4216762
View in: PubMed

13.Bailey SR, Nelson MH, Himes RA, Li Z, Mehrotra S, Paulos CM. Th17 cells in cancer: the ultimate identity crisis. Front Immunol. .5:276, 2014. PMID: 24987392 PMCID: PMC4060300
View in: PubMed

14.Rubinstein MP, Cloud CA, Garrett TE, Moore CJ, Schwartz KM, Johnson CB, Craig DH, Salem ML, Paulos CM, Cole DJ. Ex vivo interleukin-12-priming during CD8(+) T cell activation dramatically improves adoptive T cell transfer antitumor efficacy in a lymphodepleted host. J Am Coll Surg. .214(4):700-7; discussion 707-8, 2012. PMID: 22360982 PMCID: PMC3429131
View in: PubMed

15.Gattinoni L, Lugli E, Ji Y, Pos Z, Paulos CM, Quigley MF, Almeida JR, Gostick E, Yu Z, Carpenito C, Wang E, Douek DC, Price DA, June CH, Marincola FM, Roederer M, Restifo NP. A human memory T cell subset with stem cell-like properties. Nat Med. .17(10):1290-7, 2011. PMID: 21926977 PMCID: PMC3192229
View in: PubMed

16.Zhang Q, Wang H, Kantekure K, Paterson JC, Liu X, Schaffer A, Paulos C, Milone MC, Odum N, Turner S, Marafioti T, Wasik MA. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS. Blood. .118(11):3062-71, 2011. PMID: 21765024 PMCID: PMC3175783
View in: PubMed

17.Paulos CM, Carpenito C, Plesa G, Suhoski MM, Varela-Rohena A, Golovina TN, Carroll RG, Riley JL, June CH. The inducible costimulator (ICOS) is critical for the development of human T(H)17 cells. Sci Transl Med. .2(55):55ra78, 2010. PMID: 20980695
View in: PubMed

18.Zhao Y, Moon E, Carpenito C, Paulos CM, Liu X, Brennan AL, Chew A, Carroll RG, Scholler J, Levine BL, Albelda SM, June CH. Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor. Cancer Res. .70(22):9053-61, 2010. PMID: 20926399 PMCID: PMC2982929
View in: PubMed

19.Wrzesinski C, Paulos CM, Kaiser A, Muranski P, Palmer DC, Gattinoni L, Yu Z, Rosenberg SA, Restifo NP. Increased intensity lymphodepletion enhances tumor treatment efficacy of adoptively transferred tumor-specific T cells. J Immunother. .33(1):1-7, 2010. PMID: 19952961 PMCID: PMC3247626
View in: PubMed

20.Paulos CM, June CH. Putting the brakes on BTLA in T cell-mediated cancer immunotherapy. J Clin Invest. .120(1):76-80, 2009. PMID: 20038807 PMCID: PMC2798708
View in: PubMed

21.Gattinoni L, Zhong XS, Palmer DC, Ji Y, Hinrichs CS, Yu Z, Wrzesinski C, Boni A, Cassard L, Garvin LM, Paulos CM, Muranski P, Restifo NP. Wnt signaling arrests effector T cell differentiation and generates CD8+ memory stem cells. Nat Med. .15(7):808-13, 2009. PMID: 19525962 PMCID: PMC2707501
View in: PubMed

22.Hinrichs CS, Kaiser A, Paulos CM, Cassard L, Sanchez-Perez L, Heemskerk B, Wrzesinski C, Borman ZA, Muranski P, Restifo NP. Type 17 CD8+ T cells display enhanced antitumor immunity. Blood. .114(3):596-9, 2009. PMID: 19471017 PMCID: PMC2713473
View in: PubMed

23.Boni A, Muranski P, Cassard L, Wrzesinski C, Paulos CM, Palmer DC, Gattinoni L, Hinrichs CS, Chan CC, Rosenberg SA, Restifo NP. Adoptive transfer of allogeneic tumor-specific T cells mediates effective regression of large tumors across major histocompatibility barriers. Blood. .112(12):4746-54, 2008. PMID: 18799724 PMCID: PMC2597140
View in: PubMed

24.Palmer DC, Chan CC, Gattinoni L, Wrzesinski C, Paulos CM, Hinrichs CS, Powell DJ, Klebanoff CA, Finkelstein SE, Fariss RN, Yu Z, Nussenblatt RB, Rosenberg SA, Restifo NP. Effective tumor treatment targeting a melanoma/melanocyte-associated antigen triggers severe ocular autoimmunity. Proc Natl Acad Sci U S A. .105(23):8061-6, 2008. PMID: 18523011 PMCID: PMC2409137
View in: PubMed

25.Muranski P, Boni A, Antony PA, Cassard L, Irvine KR, Kaiser A, Paulos CM, Palmer DC, Touloukian CE, Ptak K, Gattinoni L, Wrzesinski C, Hinrichs CS, Kerstann KW, Feigenbaum L, Chan CC, Restifo NP. Tumor-specific Th17-polarized cells eradicate large established melanoma. Blood. .112(2):362-73, 2008. PMID: 18354038 PMCID: PMC2442746
View in: PubMed

26.Hinrichs CS, Spolski R, Paulos CM, Gattinoni L, Kerstann KW, Palmer DC, Klebanoff CA, Rosenberg SA, Leonard WJ, Restifo NP. IL-2 and IL-21 confer opposing differentiation programs to CD8+ T cells for adoptive immunotherapy. Blood. .111(11):5326-33, 2008. PMID: 18276844 PMCID: PMC2396726
View in: PubMed

27.Abad JD, Wrzensinski C, Overwijk W, De Witte MA, Jorritsma A, Hsu C, Gattinoni L, Cohen CJ, Paulos CM, Palmer DC, Haanen JB, Schumacher TN, Rosenberg SA, Restifo NP, Morgan RA. T-cell receptor gene therapy of established tumors in a murine melanoma model. J Immunother. .31(1):1-6, 2008. PMID: 18157006 PMCID: PMC2235937
View in: PubMed

28.Paulos CM, Suhoski MM, Plesa G, Jiang T, Basu S, Golovina TN, Jiang S, Aqui NA, Powell DJ, Levine BL, Carroll RG, Riley JL, June CH. Adoptive immunotherapy: good habits instilled at youth have long-term benefits. Immunol Res. .42(1-3):182-96, 2008. PMID: 18949448 PMCID: PMC3809041
View in: PubMed

29.Paulos CM, Kaiser A, Wrzesinski C, Hinrichs CS, Cassard L, Boni A, Muranski P, Sanchez-Perez L, Palmer DC, Yu Z, Antony PA, Gattinoni L, Rosenberg SA, Restifo NP. Toll-like receptors in tumor immunotherapy. Clin Cancer Res. .13(18 Pt 1):5280-9, 2007. PMID: 17875756 PMCID: PMC2131730
View in: PubMed

30.Paulos CM, Wrzesinski C, Kaiser A, Hinrichs CS, Chieppa M, Cassard L, Palmer DC, Boni A, Muranski P, Yu Z, Gattinoni L, Antony PA, Rosenberg SA, Restifo NP. Microbial translocation augments the function of adoptively transferred self/tumor-specific CD8+ T cells via TLR4 signaling. J Clin Invest. .117(8):2197-204, 2007. PMID: 17657310 PMCID: PMC1924500
View in: PubMed

31.Wrzesinski C, Paulos CM, Gattinoni L, Palmer DC, Kaiser A, Yu Z, Rosenberg SA, Restifo NP. Hematopoietic stem cells promote the expansion and function of adoptively transferred antitumor CD8 T cells. J Clin Invest. .117(2):492-501, 2007. PMID: 17273561 PMCID: PMC1783812
View in: PubMed

32.Antony PA, Paulos CM, Ahmadzadeh M, Akpinarli A, Palmer DC, Sato N, Kaiser A, Hinrichs CS, Heinrichs C, Klebanoff CA, Tagaya Y, Restifo NP. Interleukin-2-dependent mechanisms of tolerance and immunity in vivo. J Immunol. .176(9):5255-66, 2006. PMID: 16621991 PMCID: PMC1473163
View in: PubMed

33.Paulos CM, Varghese B, Widmer WR, Breur GJ, Vlashi E, Low PS. Folate-targeted immunotherapy effectively treats established adjuvant and collagen-induced arthritis. Arthritis Res Ther. .8(3):R77, 2006. PMID: 16646988 PMCID: PMC1526647
View in: PubMed

34.Paulos CM, Reddy JA, Leamon CP, Turk MJ, Low PS. Ligand binding and kinetics of folate receptor recycling in vivo: impact on receptor-mediated drug delivery. Mol Pharmacol. .66(6):1406-14, 2004. PMID: 15371560
View in: PubMed

35.Paulos CM, Turk MJ, Breur GJ, Low PS. Folate receptor-mediated targeting of therapeutic and imaging agents to activated macrophages in rheumatoid arthritis. Adv Drug Deliv Rev. .56(8):1205-17, 2004. PMID: 15094216
View in: PubMed

36.Turk MJ, Breur GJ, Widmer WR, Paulos CM, Xu LC, Grote LA, Low PS. Folate-targeted imaging of activated macrophages in rats with adjuvant-induced arthritis. Arthritis Rheum. .46(7):1947-55, 2002. PMID: 12124880
View in: PubMed